SURESH SABBENAHALLI: Open Payments
NPI 1528372505 · SHREVEPORT, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,904 in 91 payments from 13 companies in 2025. Trend: 2023 $3,105 · 2024 $1,816 · 2025 $1,904
Food & beverage: $1,895Education: $8
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 21 | $380 |
| Janssen Pharmaceuticals, Inc | 11 | $304 |
| Alkermes, Inc. | 8 | $231 |
| ABBVIE INC. | 12 | $228 |
| E.R. Squibb & Sons, L.L.C. | 12 | $187 |
| Teva Pharmaceuticals USA, Inc. | 5 | $105 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $98 |
| Braeburn Inc. | 5 | $94 |
| LivaNova USA, Inc. | 2 | $87 |
| Otsuka America Pharmaceutical, Inc. | 4 | $81 |
Products named: INGREZZA, VRAYLAR, COBENFY, INVEGA SUSTENNA, LYBALVI, SPRAVATO, AUSTEDO XR, REXULTI.
Industry payments across LA — which companies pay providers there.
